当前位置: X-MOL 学术Nat. Rev. Cardiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved
Nature Reviews Cardiology ( IF 41.7 ) Pub Date : 2021-09-15 , DOI: 10.1038/s41569-021-00627-z
Karina Huynh 1
Affiliation  

In a clinical first, empagliflozin treatment cuts the risk of cardiovascular death and hospitalization compared with placebo in patients with heart failure with preserved ejection fraction.

中文翻译:

Empagliflozin 改善了 EMPEROR-Preserved 中 HFpEF 的临床结果

在临床上,与安慰剂相比,恩格列净治疗可降低射血分数保留的心力衰竭患者的心血管死亡和住院风险。
更新日期:2021-09-15
down
wechat
bug